Moderna has begun dosing patients in a mid-to-late stage study of its COVID-19 vaccine in children aged six months to less than 12 years, the company said on Tuesday.The study will assess the safety and effectiveness of two doses of the shot, given 28 days apart, and intends to enroll about 6,750 children in the United States and Canada.
A look at when Canada could start administering COVID-19 vaccines to teens, children The vaccine has already been authorized for emergency use in Canada and the U.S.